Download PDF
Previous article
Go back to website
Next article
If you have problems to see the content please click here
Other users also viewed these articles
One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry
Clementina López-Medina; Lucía Otero-Varela; Fernando Sánchez-Alonso; Vega Jovaní; Lorena Expósito-Pérez; Sheila Melchor-Díaz; Yanira Pérez-Vera; Paula Pretel-Ruiz; Javier Manero; Antonio Mera-Varela; Lourdes Mateo; Dolores Ruiz-Montesino; José Andrés Lorenzo-Martín; Teresa Pedraz-Penalva; Isabel Castrejón;
Reumatol Clin. 2025;21:
Clinical practice guideline on the treatment of axial spondyloarthritis and psoriatic arthritis. ESPOGUÍA 2024
Juan D. Cañete; Petra Díaz del Campo Fontecha;
10.1016/j.reumae.2025.501892
Is the use of secukinumab after anti-TNF therapy greater than expected for the risk of developing inflammatory bowel disease?
Fatih Albayrak; Mustafa Gür; Ahmet Karata¿; Süleyman Serdar Koca; Bünyamin K¿sac¿k;
Reumatol Clin. 2024;20:123-7